2023 World Conference on Lung Cancer (Posters)-EP06.03. Characteristics, Treatment Patterns and Outcomes of Real-World NSCLC Exon 20 Insertions in HER1 (EGFR) and HER2 (ERBB2)

EP06.03. Characteristics, Treatment Patterns and Outcomes of Real-World NSCLC Exon 20 Insertions in HER1 (EGFR) and HER2 (ERBB2) - PDF(Slides)

Back to course

Pdf Summary

This study examined the characteristics, treatment patterns, and outcomes of patients with non-small cell lung cancer (NSCLC) who had exon 20 insertions in the HER1 (EGFR) and HER2 (ERBB2) genes. These gene alterations have been found to drive oncogenesis in NSCLC, but they have shown limited sensitivity to conventional targeted therapies.<br /><br />The study included 38 patients who were identified from a real-world outcomes registry in Canada. The demographic and clinical characteristics of patients with EGFR-based exon 20 insertions were similar to those with ERBB2-based insertions. However, there were differences in the management of systemic therapy. EGFR-exon 20 insertions were mostly treated with cytotoxic chemotherapy, while ERBB2 insertions were managed similarly to wildtype patients, with treatment guided by PD-L1 expression, resulting in a higher use of immune checkpoint inhibitors in this subgroup.<br /><br />The study found no significant difference in treatment duration, response, or outcome between patients with EGFR or ERBB2 exon 20 insertions receiving palliative-intent systemic therapy for advanced/metastatic disease. The overall response rates and disease control rates were similar to those observed in wildtype populations.<br /><br />The use of conventional EGFR-TKI therapy in this cohort failed to provide meaningful disease control. The study suggests that further investigation is needed into the safety and efficacy of immune checkpoint inhibitors in a cohort with access to novel targeted therapies.<br /><br />Overall, this study provides insights into the characteristics and management of patients with NSCLC exon 20 insertions in the HER1 and HER2 genes, highlighting the need for alternative treatment approaches for these patients.

Asset Subtitle

Amanda Gibson

Meta Tag

Speaker Amanda Gibson

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

non-small cell lung cancer

exon 20 insertions

HER1

EGFR

HER2

ERBB2

targeted therapies

immune checkpoint inhibitors

treatment duration

disease control rates